Estarylla

Pharmacies, wholesalers, and distributors that stock oral contraceptives need a product they can dispense with confidence and reorder without disruption. Estarylla from Xiromed answers that need. This combined oral contraceptive tablet pairs Norgestimate with Ethinyl Estradiol in a single fixed-dose formulation, giving your inventory a dependable, widely prescribed option backed by consistent manufacturing and clear specifications.

Product Overview

Estarylla is a combined oral contraceptive (COC) tablet supplied at a strength of 0.25 mg / 0.035 mg. Each carton holds three blister cards of 28 tablets, for a total of 84 tablets per pack. That 3 x 28 configuration lines up with standard 28-day contraceptive cycles, which reduces refill gaps for patients and simplifies dispensing routines for your team.

Every active tablet delivers a fixed dose of both hormones, which removes the guesswork that separate-component regimens can introduce and helps pharmacists dispense with precision. The predictable pack layout also keeps your reorder rhythm clean, so stock moves through your shelf in step with patient demand.

For distributors building out a women’s health or contraceptive category, Estarylla slots in cleanly. It fills a well-established therapeutic need, ships in a familiar pack size, and comes with the documentation your compliance and procurement teams expect from a reliable supplier.

Active Ingredients and Their Roles

The value of any combined oral contraceptive lies in how its two hormones work together. Estarylla brings together two well-known agents, each with a defined purpose within the regimen.

Norgestimate (0.25 mg) is the progestin component. Norgestimate is a well-established progestin in contraceptive practice, and its pairing with ethinyl estradiol represents a long-recognized combination. Within the fixed-dose tablet, it supports the core contraceptive effect and works alongside the estrogen to shape the overall hormonal profile.

Ethinyl Estradiol (0.035 mg) is the estrogen component. In a combined oral contraceptive, the estrogen works alongside the progestin to support cycle regulation and contribute to the overall contraceptive effect. The 0.035 mg dose reflects a familiar low-dose estrogen level, aligning Estarylla with widely used prescribing patterns.

By delivering both hormones in one daily oral tablet, Estarylla keeps the regimen straightforward. Patients take a single tablet each day rather than managing multiple products, and dispensers handle one SKU instead of coordinating separate items. That simplicity supports adherence and streamlines day-to-day pharmacy operations.

Indications and Use

Estarylla belongs to the combined oral contraceptive category and is intended for use under the direction of a qualified healthcare professional. Products of this type are commonly prescribed for the prevention of pregnancy in patients who choose to use an oral contraceptive.

Prescribing decisions, dosing, patient selection, screening, and treatment duration should always follow the approved product labeling and the clinical judgment of the treating physician. This description is written for licensed professionals and authorized trade partners and is not a substitute for the full prescribing information. Always confirm indications, contraindications, and directions against the current labeling before dispensing.

Pack Configuration and Key Details

Clear specifications reduce ordering errors and keep procurement moving. Confirm the following before adding Estarylla to your catalog:

Detail	Specification
Product name	Estarylla
Active ingredients	Norgestimate / Ethinyl Estradiol
Strength	0.25 mg / 0.035 mg per tablet
Pack size	3 x 28 tablets (84 tablets total)
Dosage form	Oral tablet
Category	Combined oral contraceptive
Supplier	Xiromed
NDC	Contact the Xiromed team to confirm current NDC details

The three-card layout maps to consecutive 28-day cycles, so patients move through a full treatment period without needing an early refill. For pharmacy operations, that means fewer partial-supply issues and a cleaner, more predictable reorder pattern.

Why Source Through Xiromed

Reliable supply matters as much as the product itself. Xiromed manufactures its portfolio to meet stringent regulatory standards, and Estarylla holds to the same benchmark. Each batch is produced with consistency in mind, so your supply chain receives a product that performs the same way order after order.

Sourcing Estarylla directly through Xiromed gives buyers verified specifications, confirmed product codes for accurate matching, and a supply relationship built around the demands of pharmacies and distributors. When availability and documentation both matter, working with a manufacturer that prioritizes each makes procurement simpler.

If you are expanding your contraceptive offering or securing a steady source for an existing line, Estarylla is a straightforward addition. To order or request further product information, including current NDC details, connect with the Xiromed team to confirm the exact 0.25 mg / 0.035 mg, 3 x 28 configuration for your inventory.

---

This information is intended for licensed healthcare professionals, pharmacies, and authorized distributors. Estarylla is a prescription product and should be used only as directed by a qualified healthcare provider in accordance with the approved product labeling. Product availability, specifications, and regulatory status may vary by region. Refer to the full prescribing information before dispensing.